A Phase II Study Evaluating Safety and Mucosal Repair of AZD7798 in Patients with Crohn’s Disease and an Ileostomy - Callisto

Study identifier:D9690C00006

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:2024-514407-33-00

Will Be Recruiting

Official Title

A Participant- and Investigator-blind, Randomised, Placebo-controlled Phase II Study to Evaluate Safety, Tolerability, and Mucosal Repair with AZD7798 in Patients with Active Ileal Crohn’s Disease and an Ileostomy (CALLISTO)

Medical condition

Crohn’s disease

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD7798

Sex

All

Estimated Enrollment

30

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 16 Dec 2024
Estimated Primary Completion Date: 05 Jan 2026
Estimated Study Completion Date: 16 Feb 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria